1-3 of 3
Juliet A. Williams
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors

Yogesh K. Chutake, Michele F. Mayo, Nancy Dumont, Jessica Filiatrault, Susanne B. Breitkopf, Patricia Cho, Dapeng Chen, Vaishali S. Dixit, William R. Proctor, Eric W. Kuhn, Sarah Bollinger Martinez, Alice A. McDonald, Jianfeng Qi, Kan-Nian Hu, Rahul Karnik, Joseph D. Growney, Kirti Sharma, Stefanie S. Schalm, Ashwin M. Gollerkeri, Nello Mainolfi, Juliet A. Williams, Matthew M. Weiss
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther OF1–OF14.
https://doi.org/10.1158/1535-7163.MCT-24-0306
Published: 03 January 2025
View article titled, KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Open the PDF for KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors in another window
Includes: Supplementary data
Journal Articles

Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies

Haihui Lu, Ryan D. Molony, Dongshu Chen, Sunyoung Jang, Babette Wolf, Stefan Ewert, Meghan Flaherty, Fangmin Xu, Sinan Isim, Yeonju Shim, Christina Dornelas, Nicole Balke, Xavier Charles Leber, Meike Scharenberg, Johanna Koelln, Eugene Choi, Rebecca Ward, Jennifer Johnson, Thomas Calzascia, Isabelle Isnardi, Juliet A. Williams, Pieter L. Lindenbergh, Niels W.C.J. van de Donk, Tuna Mutis, Heather Huet, Emma Lees, Matthew J. Meyer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (10): 2089–2104.
https://doi.org/10.1158/1535-7163.MCT-19-0003
Published: 02 October 2020
View article titled, Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies
Open the PDF for Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies in another window
Includes: Supplementary data
Journal Articles

Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAFV600-Mutant Melanoma Patient-Derived Xenografts

Tianshu Feng, Javad Golji, Ailing Li, Xiamei Zhang, David A. Ruddy, Daniel P. Rakiec, Felipe C. Geyer, Jane Gu, Hui Gao, Juliet A. Williams, Darrin D. Stuart, Matthew J. Meyer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2421–2432.
https://doi.org/10.1158/1535-7163.MCT-19-0028
Published: 02 December 2019
View article titled, Distinct Transcriptional Programming Drive Response to MAPK Inhibition in <em>BRAF</em><sup>V600</sup>-Mutant Melanoma Patient-Derived Xenografts
Open the PDF for Distinct Transcriptional Programming Drive Response to MAPK Inhibition in <em>BRAF</em><sup>V600</sup>-Mutant Melanoma Patient-Derived Xenografts in another window
Includes: Supplementary data